Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).